In a recent move, Hunan Mabgeek Biotechnology Co, a portfolio company of Zhongshan Venture Capital, submitted its IPO application to the Hong Kong Stock Exchange.

As the first investment project of Zhongshan's biomedical angel fund, this marks a new phase for the venture in accessing international capital markets. The listing will provide broader financial resources and growth opportunities for scaling R&D, expanding market reach, and attracting top talent, while enhancing its global visibility in the biomedical sector.

Founded in 2016, Mabgeek Biotechnology focuses on developing innovative antibody drugs for autoimmune and inflammatory diseases, aiming to deliver breakthrough therapies to patients worldwide. Zhongshan Venture Capital, a subsidiary of Zhongshan Investment Holdings, invested in the Mabgeek Biotechnology in 2025 to accelerate its innovation in drug development.